Translate this page into:
Theranostic role of radiolabelled RGD peptide in the treatment of radioiodine-resistant thyroid cancer: A novel agent
*For correspondence: sood99@yahoo.com
-
Received: ,
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
A 47 yr old female†, a known case of papillary carcinoma thyroid, post-total thyroidectomy and radioiodine treatment (I-131, cumulative dose of 716 mCi), presented to the department of Nuclear Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India, in June 2019, with rising serum thyroglobulin (Tg) level of 13,840 ng/ml and anti-Tg of 34.53 IU/ml. Ultrasonography of the neck revealed a lobulated heterogeneous soft tissue mass in the midline and supraclavicular region, along with bilateral subcentimetric cervical lymph nodes. There was markedly elevated serum Tg and negative whole-body radioiodine scan, also known as TENIS (Thyroglobulin Elevation with Negative Iodine Scintigraphy) syndrome (Fig. 1). The patient was evaluated with whole-body gallium-68 (Ga-68) RGD positron emission tomography/computed tomography imaging (Fig. 2) for the staging and tumour tracer avidity for therapeutic potential with radionuclide therapy. RGD is an arginine–glycine–aspartic acid-based synthetic peptide targeting integrin αvβ3, which are overexpressed on endothelial cells of neovasculature and tumour cells. Lutetium-177 (Lu-177) RGD (~120 mCi) radionuclide therapy was given to the patient in view of tracer avidity in the residual/recurrent disease, and post-therapy images showed effective localization of tracer (Fig. 3). Lu-177 RGD may be a novel approach of treatment for radioiodine refractory thyroid cancer patients. Followup of the patient after four weeks of therapy showed significant reduction in serum Tg level from 13,840 ng/ml to 5,280 ng/ml with significant clinical improvement. The patient was planned for the second dose of Lu-177 RGD radionuclide therapy in view of favourable response.
- Whole-body (anterior and posterior) low dose radioiodine diagnostic scan done after 48 h of 2 mCi of I-131administration. No abnormal tracer uptake was seen anywhere in the body apart from physiological tracer distribution.
- (A) Whole-body Ga-68 RGD positron emission tomography(PET)/computed tomography (CT) (3.25 mCi) for residual disease and tracer avidity evaluation showed increased tracer uptake in the neck region (SUVmax 8.8) on maximum intensity projection (MIP) image. (B) Transaxial PET/CT and (C) computed tomography images showing tracer uptake in heterogeneously enhancing soft tissue lesion in the anterior of neck with tracheostomy tube in situ (arrows). (D and E) Another focal tracer uptake was seen in lytic lesion in the manubrium.
- Whole-body (anterior and posterior) post-Lu-177 RGD radionuclide therapy images at 17 h (A and B) and 48 h (C and D) showing increased tracer uptake in neck region (arrowheads) anteriorly corresponding to tracer avid soft tissue lesion seen in pre-therapy Ga-68 RGD PET/CT scan (Fig. 2). Liver, spleen and kidneys showed physiological tracer uptake.
Conflicts of Interest: None.
